Zamicastat clinical trials
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses zamicastat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2018 (7)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 2 |
| 2018 | 7 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
Furosemide (1) · PNU-100480 (1) · Sildenafil (1) · Warfarin (1) · Bosentan (1)
Studies
Open first, then newest update. How each study uses zamicastat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and FurosemideCompletedPhase 1Bial - Portela C S.A.NCT07173738Written as BIA 5-1058
- Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)CompletedPhase 2Bial - Portela C S.A.NCT04316143Written as Oral zamicastat
- Safety and Efficacy of BIA 5-1058 in PAHCompletedPhase 2Bial - Portela C S.A.NCT06009185Written as Oral zamicastat
- Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of SildenafilCompletedPhase 1Bial - Portela C S.A.NCT04994860Written as BIA 5-1058
- Effect of BIA 5-1058 400 mg on Warfarin PharmacokineticsCompletedPhase 1Bial - Portela C S.A.NCT04994119Written as BIA 5-1058
- Effect of Food on BIA 5-1058CompletedPhase 1Bial - Portela C S.A.NCT04991155Written as BIA 5-1058
- Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of BosentanCompletedPhase 1Bial - Portela C S.A.NCT04991207Written as BIA 5-1058
- Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058TerminatedPhase 1Bial - Portela C S.A.NCT04991194Written as BIA 5-1058
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058CompletedPhase 1Bial - Portela C S.A.NCT03708146Written as BIA 5-1058
- Effect of BIA 5 1058 on Cardiac RepolarizationCompletedPhase 1Bial - Portela C S.A.NCT03489005Written as BIA 5-1058
- Effect of BIA 5-1058 on the Steady State Pharmacokinetics of TreprostinilCompletedPhase 1Bial - Portela C S.A.NCT04675944Written as BIA 5-1058
- Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.CompletedPhase 1Bial - Portela C S.A.NCT02151994Written as BIA 5-1058
Codes
What other systems call zamicastat · ClinicalTrials.gg INT001059
- MeSH (NLM) C000630084zamicastatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) YLU32D0DNVZAMICASTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27294585zamicastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152947ZamicastatOne source FDA
- DrugBank DB12389One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630084 | zamicastat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | YLU32D0DNV | ZAMICASTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294585 | zamicastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152947 | Zamicastat | One source FDA |
| DrugBank | DB12389 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.